SRX is not using it for the first line therapy!
That's why the SP fell massively....But the first line therapy was the primary use intended to maximise revenues.
It's not a total failure but it is a big disappointment to the market.
BUT MSB doesn't have such problems! And it has a platform of technology applications for the MPC stem cells.
Still trying to discredit me? Why bother?
What I say on HC can't influence other posters ....or the SP...can it?
fundamental msb (no chart talk), page-9
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.015(1.49%) |
Mkt cap ! $1.164B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.04 | 94.0¢ | $11.76M | 11.90M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 206912 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 37637 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |